Physician profile
Michael Spicer
NPI 1831176858
$7,464.80
in general payments reported to CMS, 2019-2025
36 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $1,166 · 2021: $850 · 2022: $930 · 2023: $936 · 2024: $795 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,813.03 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $785.19 | 2019-2025 | |
| Janssen Biotech, INC. | $582.57 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $517.79 | 2019-2023 | Dupixent |
| Pfizer INC. | $374.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $337.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $310.28 | 2019-2025 | Ilumya |
| Ucb, INC. | $308.50 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $303.65 | 2019-2025 | Adbry |
| Sebela Pharmaceuticals INC. | $271.42 | 2019-2020 | |
| Genentech USA, INC. | $205.49 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $166.09 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $162.98 | 2019-2020 | |
| Lilly USA, LLC | $162.74 | 2019-2025 | Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $153.20 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $153.19 | 2020-2025 | Klisyri |
| Incyte Corporation | $131.11 | 2022-2025 | Opzelura |
| Amgen INC. | $124.81 | 2019-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Botanix Sb INC | $57.49 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $56.43 | 2023-2024 | Vtama |
| Sandoz INC. | $55.26 | 2019 | |
| Vyne Pharmaceuticals INC. | $55.23 | 2020-2021 | |
| Dermira, INC. | $40.53 | 2019-2020 | |
| Galderma Laboratories, L.P. | $38.54 | 2024-2025 | Nemluvio, Aklief |
| Merz North America, INC. | $26.38 | 2019 | |
| Verrica Pharmaceuticals INC. | $23.40 | 2025 | Ycanth |
| Teleflex LLC | $23.33 | 2025 | Arrow |
| Sensus Healthcare, INC. | $22.57 | 2020 | |
| Dusa Pharmaceuticals, INC. | $21.35 | 2019 | |
| Medline Industries LP | $19.48 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.95 | 2023 | Spevigo |
| Icad, INC | $13.51 | 2023 | Axxent Surface Controller |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Strata Skin Sciences, INC. | $12.02 | 2021 | |
| Organon LLC | $3.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spicer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.